Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial
- 1 January 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Patient Care and STDs
- Vol. 37 (1), 53-59
- https://doi.org/10.1089/apc.2022.0168
Abstract
Cabotegravir and rilpivirine long-acting (LA) antiretroviral therapy (ART) demonstrated similar safety and efficacy in maintaining viral suppression among participants switching from daily oral to LA ART in the Extension Phase of the FLAIR trial. The Phase IIIb SOLAR study comparing efficacy and safety of daily oral versus LA ART every 2 months allowed participants and health care providers (HCPs) to choose an oral lead-in (OLI) before LA initiation or proceed by immediately starting with injections (SWI). We conducted an online survey among SOLAR HCPs (n = 110) in 13 countries to assess reasons for choosing OLI versus SWI. Logistic regression was used to identify factors influencing this decision. Thirty-two percent of HCPs reported a future preference to use OLI, whereas 54% reported a future preference for SWI. HCPs had greater odds of reporting future intentions for SWI if they were from Continental Europe versus North America [adjusted odds ratio (aOR): 3.83, p < 0.05], from sites with a greater number of participants who initiated LA ART without OLI (aOR: 1.56, p < 0.01), and those who reported comfort with the medication safety profile (aOR: 6.39, p < 0.01). HCPs who participated in LA ART trials before SOLAR had decreased odds of reporting a preference for SWI compared to those with no prior LA ART trial experience (aOR: 0.11; p < 0.01). Results indicated higher intentions to SWI over OLI among HCPs initiating participants on LA ART. A major factor associated with SWI was provider comfort with safety data, reinforcing the role of continued training regarding an SWI approach.Keywords
This publication has 24 references indexed in Scilit:
- ART Adherence Among Men Who Have Sex with Men Living with HIV: Key Challenges and OpportunitiesCurrent HIV/AIDS Reports, 2020
- Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infectionAIDS Care, 2020
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionThe New England Journal of Medicine, 2020
- Correlates of and barriers to ART adherence among adherence-challenged people living with HIV in southern IndiaAIDS Care, 2020
- Cross-sectional evaluation of perceived health care provider engagement, self-efficacy, and ART adherence in people living with HIV/AIDSAIDS Care, 2019
- Twenty Years Of Antiretroviral Therapy For People Living With HIV: Global Costs, Health Achievements, Economic BenefitsHealth Affairs, 2019
- Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and SpainPLOS ONE, 2018
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialThe Lancet, 2017
- HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment ProgrammesPLoS Medicine, 2012
- HIV treatment as prevention and HPTN 052Current Opinion in HIV and AIDS, 2012